Health Canada is reshaping how medicines move through the regulatory system, pitching its agile licensing framework as a way ...

Cambridge, USA-based Agios Pharmaceuticals’ shares closed down 51% at $22.34 yesterday, after the company announced top-line ...

US biotech major Amgen’s Imdelltra (tarlatamab-dlle) received full approval from the us Food and Drug Administration (FDA) on ...

Icelandic biosimilars company Alvotech and privately-held UK firm Advanz Pharma today announced that the European Commission ...

Ireland-based Alkermes (Nasdaq: ALKS) has upped its offer to buy Avadel Pharmaceuticals (Nasdaq: AVDL). Under the improved ...

US biotech Moderna has held an analyst day event providing updates on its mRNA pipeline progress and a three-year plan for ...

Swiss pharma giant Novartis today rolled forward its mid-term guidance to 2025-2030 with a sales compound annual growth rate ...

Swiss pharma giant Novartis (NOVN: VX) has announced plans to expand its operations in North Carolina, USA, creating a new ...

UK pharma major AstraZeneca (LSE: AZN) has gained US approval for Koselugo (selumetinib) in adults with neurofibromatosis ...

Industry analyst GlobalData has highlighted the significance of US pharma major Merck's (NYSE: MRK) plan to buy US biotech ...

Sino-American immunotherapy-focused biotech LTZ Therapeutics and UK pharma major GSK have entered into a strategic research ...

Regeneron Pharmaceuticals has announced that the European Commission (EC) has approved the PD-1 inhibitor Libtayo (cemiplimab) as an adjuvant treatment for adult patients with cutaneous squamous cell ...